Olopatadine HCL 0.1% Ophthalmic Solution
Awarded on February 15, 2023. Full description on SAM.gov.
Overview
- Posted
- September 24, 2026
- Notice type
- Award Notice
- NAICS
- 325412: Pharmaceutical Preparation Manufacturing
- Agency
- Department of WarDEFENSE LOGISTICS AGENCY
Notice details
- Office
- TROOP SUPPORT MEDICAL.DLA TROOP SUPPORT
- Place of performance
- Ontario, Canada
- Last updated
- Oct 28, 2026
- First published
- Last updated on SAM.gov
- Award date
- Feb 15, 2023
- Award amount (SAM.gov award notice)
- $17.6M
Identifiers
- Solicitation number
- SPE2D222R0117
- Notice ID
- df6c2375129a40959545546683d370c4
- Award number (PIID)
- SPE2D223D0007
Description
Modification SPE2D223D0007 P00013 No-Cost Settlement Termination for Convenience.
Modification SPE2D223D0007 P00012 is issued to incorporate clause 52.222-90, Addressing DEI Discrimination by Federal Contractors (DEVIATION 2026-O0040, REVISION 1) (APR 2026).
Modification SPE2D223D0007 P00011 to change the Manufacturer, Place of Performance and NDC for Olopatadine HCL 0.1% Ophthalmic Solution 5ML Bottle.
Modification SPE2D223D0007 P00010 to update new POC for Golden State Medical Supply, Inc. cage code 1HT23.
Modification SPE2D223D0007 P00008 to exercise Option Year 3 effective February 15, 2026 through February 14, 2027.
Modification SPE2D223D0007 P00007 is modified in accordance with DoD Class Deviation 2025-O0003.
Modification SPE2D223D0007 P00006 to exercise Option Year 2 effective February 15, 2025 through February 14, 2026.
Modification SPE2D223D0007 P00005 to incorporate FAR 52.204-30 Federal Acquisition Supply Chain Security Act Orders language into solicitation for subject contract.
Modification SPE2D223D0007 P00004 to exercise Option Year 1 effective February 15, 2024 through February 14, 2025.
Modification SPE2D223D0007 P00003 to incorporate Drug Supply Chain Security Act language into solicitation for subject contract.
Modification SPE2D223D0007 P00002 to incorporate clause FAR 52.204-27 Prohibition on a ByteDance Covered Application (JUN 2023) into subject contract.
Modification P00001 SPE2D2-23-D-0007 revising the the price effective date and ship date from April 16, 2023 to February 28, 2023.
Contract Award for Olopatadine HCL 0.1% Opthtalmic Solution 5ML Bottle
Award Overview
Award Number
SPE2D223D0007
Award Amount (SAM.gov award notice)
$17.6M
Award Date
Feb 15, 2023
Awardee
Awardee UEI
GQLDJJ8AQNN5
Awardee CAGE Code
1HT23
Awardee Address
Camarillo, CA 93012, UNITED STATES
Line Item Number
0001
Original Solicitation
Notice ID: df6c2375129a40959545546683d370c4
Posted Date: Sep 24, 2026
Original Response Deadline: Not specified
More From This Vendor
Top 5 most recent
- $147.36Signed Aug 12, 2026
- $535.44Signed Aug 12, 2026
- $27.3Signed Aug 12, 2026
- $85.96Signed Aug 10, 2026
- $133.86Signed Aug 7, 2026
Contacts
Contracting Officer
Primary Contact
Secondary Contact
Documents
Files (14)
- Download
T4C Modification P00013 SPE2D223D0007 - Bilaterally Signed.pdf
168 KBAdded in Award Notice version 9Posted - Download
Modification P00012 SPE2D223D0007.PDF
176 KBAdded in Award Notice version 9Posted - Download
Signed Olopatadine HCL Oph Sol SPE2D223D0007 P00011 Mfg NDC Change.pdf
237 KBAdded in Award Notice version 8Posted - Download
Modification P00010 SPE2D223D0007.PDF
171 KBAdded in Award Notice version 8Posted - Download
Modification P00008 SPE2D223D0007 Option Year 3.PDF
25 KBAdded in Award Notice version 7Posted - Download
Modification P00007 SPE2D223D0007.PDF
197 KBAdded in Award Notice version 7Posted - Download
Option Year 2 Modification P00006 SPE2D223D0007.PDF
25 KBAdded in Award Notice version 6Posted - Download
Modification P00005 SPE2D223D0007.PDF
188 KBAdded in Award Notice version 6Posted - Download
Option Year 1 Modification P00004 SPE2D2-23-D-0007.PDF
25 KBAdded in Award Notice version 5Posted - Download
Signed SPE2D223D0007 P00003.pdf
867 KBAdded in Award Notice version 4Posted - Download
SF30_SPE2D223D0007P00002.PDF
173 KBAdded in Award Notice version 4Posted - Download
Signed Modification P00001 SPE2D2-23-D-0007.pdf
109 KBAdded in Award Notice version 3Posted - Download
Signed Award SPE2D2-23-D-0007 Olopatadine HCL 0.1% Ophthalmic Solution.pdf
807 KBAdded in Award Notice version 2Posted - Download
Olopatadine HCL 0.1% Ophthalmic Solution 5ML National Contract Solicitation SPE2D221R0117.pdf
1.3 MBAdded in Solicitation version 2Posted
Lifecycle
- 1Version 1Solicitation
Olopatadine HCL 0.1% Ophthalmic Solution
- 2Version 2Award Notice
Type changed from Solicitation to Award Notice
Olopatadine HCL 0.1% Ophthalmic Solution
- 3Version 3Award Notice
Olopatadine HCL 0.1% Ophthalmic Solution
- 4Version 4Award Notice
Olopatadine HCL 0.1% Ophthalmic Solution
- 5Version 5Award Notice
Olopatadine HCL 0.1% Ophthalmic Solution
- 6Version 6Award Notice
Olopatadine HCL 0.1% Ophthalmic Solution
- 7Version 7Award Notice
Olopatadine HCL 0.1% Ophthalmic Solution
- 8Version 8Award Notice
Olopatadine HCL 0.1% Ophthalmic Solution
- 9Version 9Award NoticeCurrent
Olopatadine HCL 0.1% Ophthalmic Solution
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
The Defense Logistics Agency is issuing a solicitation for a national requirements contract for Epinephrine Injectors. Procurement details follow. Epinephrine 0.3 MG/0.3 ML Injection, Auto-Injector 2S in 2 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency. A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov. Interested parties should contact Jeremy Brown at (445) 737-5419, (jeremy.brown@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current solicitation date is October of 2026. | - | Solicitation | 11/30/2026 |
The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Fentanyl Citrate Injection Solution. Procurement details follow. Fentanyl (PF) 50 MCG/ML Injection Solution in 1 ML, 2 ML, 5 ML,10 ML, 20 ML and 50 ML in Vials or Ampules, Pack Size of 1, 2, 5, 10, 20, and 50. Competition will be restricted to domestic sources (vendors providing Active Pharmaceutical Ingredients (API) and Final Dosage Forms (FDF) manufactured domestically), the procurement will be competed among all qualified domestic manufacturers. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of War (DoW), Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency. A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov/. Interested parties should contact Nancy Fernandez at (445) 737-0731 or Nancy.Fernandedz@dla.mil with any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is November/December of 2026. DLA reserves the right to issue the solicitation before or after the projected solicitation date. | - | Pre-Solicitation | Open |
This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. Item 0001: OXYGEN, USP, FILLED CYLINDER, SIZE D, 95GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-132-5181 Shall be made in accordance with MIL-O-37997 DATED 18 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. Item 0002: OXYGEN, USP, FILLED CYLINDER, SIZE H, 1650 GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-132-5199 Shall be made in accordance with MIL-O-37997 DATED 18 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. Item 0003: NITROUS OXIDE, USP, FILLED CYLINDER, SIZE D, 250 GAL, TYPE I-DOT 3AA STEEL NSN: 6505-00-130-1920 Shall be made in accordance with MIL-N-37996 DATED 24 DECEMBER 1985 (attached) and changes listed in the attachment to this notice. ----------------------------------------------------- The Defense Logistics Agency Troop Support is seeking sources capable of providing the Medical Gas Cylinder in accordance with the Military Specifications listed above. NOTE: Only Type I-DOT 3AA STEEL Medical Gas Cylinders are acceptable. If your firm currently manufactures or distributes Type I-DOT 3AA STEEL Medical Gas Cylinders in accordance with the Military Specifications and changes attached, please provide information with respect to the following: Source and Part Number being supplied for each type of cylinder Place of manufacture for each type of cylinder Source for the Medical Gases Current unit sale price for each type of cylinder prefilled with the medical grade gas Estimated annual capacity for each type of cylinder/medical grade gas Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for the ATNAA. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002. Your response to this RFI may be submitted electronically via emailed to Jessica De La Hoz, Contracting Officer, Phone: 445-737-3623, Email: Jessica.DeLaHoz@dla.mil | - | Market Research | 11/15/2026 |
Radiopharmaceutical microspheres for William Beaumont Army Medical Center (WBAMC), Fort Bliss, TX, to support ongoing selective internal radiation therapy (SIRT) for patients presenting with unresectable metastic liver tumores secondary to colorectal cancer. | - | Awarded | Open |
Please see attached for the sources sought notice/market research survey and MPID. | - | Market Research | 11/30/2026 |
Additional Details
Solicitation Number
SPE2D222R0117
Archive Date
Feb 15, 2028
Place of Performance Country
CANADA
Office Address
PHILADELPHIA, PA, 19111